Patents by Inventor Bhuwan Bhaskar MISHRA

Bhuwan Bhaskar MISHRA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymorphic forms of Afatinib free base and Afatinib dimaleate
    Patent number: 11390612
    Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: July 19, 2022
    Assignee: Fresenius Kabi Oncology Ltd.
    Inventors: Walter Cabri, Saswata Lahiri, Bhuwan Bhaskar Mishra, Abul Azim, Nilendu Panda, Poli Reddy Bhavanam, Krishanu Ray, Nikunj Kachhadia, Kumber Singh
  • POLYMORPHIC FORMS OF AFATINIB FREE BASE AND AFATINIB DIMALEATE
    Publication number: 20210024506
    Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 28, 2021
    Applicant: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Walter CABRI, Saswata LAHIRI, Bhuwan Bhaskar MISHRA, Abul AZIM, Nilendu PANDA, Poli Reddy BHAVANAM, Krishanu RAY, Nikunj KACHHADIA, Kumber SINGH
  • Polymorphic forms of Afatinib free base and Afatinib dimaleate
    Patent number: 10800763
    Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: October 13, 2020
    Assignee: Fresenius Kabi Oncology Ltd.
    Inventors: Walter Cabri, Saswata Lahiri, Bhuwan Bhaskar Mishra, Abul Azim, Nilendu Panda, Poli Reddy Bhavanam, Krishanu Ray, Nikunj Kachhadia, Kumber Singh
  • POLYMORPHIC FORMS OF AFATINIB FREE BASE AND AFATINIB DIMALEATE
    Publication number: 20180312494
    Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.
    Type: Application
    Filed: June 10, 2016
    Publication date: November 1, 2018
    Applicant: FRESENIUS KABI ONCOLOGY LTD.
    Inventors: Walter CABRI, Saswata LAHIRI, Bhuwan Bhaskar MISHRA, Abul AZIM, Nilendu PANDA, Poli Reddy BHAVANAM, Krishanu RAY, Nikunj KACHHADIA, Kumber SINGH
  • Process for the preparation of bendamustine hydrochloride
    Patent number: 9643932
    Abstract: The present invention relates to an improved process for the synthesis of bendamustine, in particular, bendamustine hydrochloride of the formula (VI) and its intermediate 1-methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula (V), both having a purity of ?99%, which is simple, convenient, economical, does not use hazardous chemicals and is industrially viable.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 9, 2017
    Assignee: Fresenius Kabi Oncology Limited
    Inventors: Bhuwan Bhaskar Mishra, Nikunj Shambhubhai Kachhadia, Vinod Singh Tomar, Saswata Lahiri
  • Amorphous form of cabazitaxel and process for its preparation
    Patent number: 9199953
    Abstract: An amorphous form of cabazitaxel is disclosed. It is preferably characterized by an X-ray powder diffraction (XRD) pattern as depicted in FIG. 1. It is prepared by (a) preparing a solution of cabazitaxel in a suitable solvent and mixture thereof; and (b) recovering the amorphous forms of cabazitaxel from the solution by removal of the solvent.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: December 1, 2015
    Assignee: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Saswata Lahiri, Bhuwan Bhaskar Mishra, Vijay Ojha, Nilendu Panda, Sonu Prasad Shukla
  • Process for the preparation of bendamustine hydrochloride
    Patent number: 9108924
    Abstract: The present invention relates to an improved process for the synthesis of bendamustine, in particular, bendamustine hydrochloride of the formula (VI) and its intermediate 1-methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula (V), both having a purity of ?99%, which is simple, convenient, economical, does not use hazardous chemicals and is industrially viable.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: August 18, 2015
    Assignee: Fresenius Kabi Oncology Limited
    Inventors: Bhuwan Bhaskar Mishra, Nikunj Shambhubhai Kachhadia, Vinod Singh Tomar, Saswata Lahiri
  • PROCESS FOR THE PREPARATION OF BENDAMUSTINE HYDROCHLORIDE
    Publication number: 20150105561
    Abstract: The present invention relates to an improved process for the synthesis of bendamustine, in particular, bendamustine hydrochloride of the formula (VI) and its intermediate 1-methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula (V), both having a purity of ?99%, which is simple, convenient, economical, does not use hazardous chemicals and is industrially viable.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Inventors: Bhuwan Bhaskar Mishra, Nikunj Shambhubhai Kachhadia, Vinod Singh Tomar, Saswata Lahiri
  • Process for the preparation of cabazitaxel
    Patent number: 9000193
    Abstract: The present invention discloses a process for the preparation of 4-acetoxy-2?-benzoyloxy-5?,20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I).
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: April 7, 2015
    Assignee: Fresenius Kabi Oncology Limited
    Inventors: Saswata Lahiri, Nitin Gupta, Abul Azim, Nilendu Panda, Bhuwan Bhaskar Mishra, Sunil Sanghani
  • PROCESS FOR THE PREPARATION OF CABAZITAXEL
    Publication number: 20150057454
    Abstract: The present invention discloses a process for the preparation of 4-acetoxy-2?-benzoyloxy-5?,20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2 R,35)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I).
    Type: Application
    Filed: November 5, 2014
    Publication date: February 26, 2015
    Inventors: Saswata Lahiri, Nitin Gupta, Abul Azim, Nilendu Panda, Bhuwan Bhaskar Mishra, Sunil Sanghani
  • Crystalline forms of cabazitaxel and process for preparation thereof
    Patent number: 8901322
    Abstract: The present invention provides Crystalline Forms of 4-acetoxy-2?-benzoyloxy-5?-20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate, i.e Cabazitaxel. The present invention also discloses methods for the preparation of Crystalline Forms of Cabazitaxel and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: December 2, 2014
    Assignee: Fresenius Kabi Oncology Limited
    Inventors: Saswata Lahiri, Rajesh Srivastava, Bhuwan Bhaskar Mishra, Shatrughan Sharma, Vijay Ojha, Nilendu Panda, Sandeep Kumar, Sonu Prasad
  • Process for the preparation cabazitaxel
    Patent number: 8901327
    Abstract: The present invention discloses a process for the preparation of 4-acetoxy-2?-benzoyloxy-5?,20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I).
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: December 2, 2014
    Assignee: Fresenius Kabi Oncology Limited
    Inventors: Saswata Lahiri, Nitin Gupta, Abul Azim, Nilendu Panda, Bhuwan Bhaskar Mishra, Sunil Sanghani
  • PROCESS FOR THE PREPARATION CABAZITAXEL
    Publication number: 20140058119
    Abstract: The present invention discloses a process for the preparation of 4-acetoxy-2?-benzoyloxy-5?,20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I).
    Type: Application
    Filed: September 24, 2012
    Publication date: February 27, 2014
    Applicant: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Saswata LAHIRI, Nitin GUPTA, Abul AZIM, Nilendu PANDA, Bhuwan Bhaskar MISHRA, Sunil SANGHANI